Company News

Share this article:
Merck struck a licensing deal with Portola Pharmaceuticals for betrixaban, an experimental anti-blood clotting drug.  According to an AP report, Merck will pay Portola $50 million initially, and a possible total of $470 million if certain goals are met.

Pfizer will appeal the Canadian Federal Court's decision that deemed a patent for Norvasc invalid. The civil action was brought by Ratiopharm, a generics manufacturer. Ratiopharm was granted permission to sell a generic version of the hypertension drug, based on the decision.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.